









市場行情
/
股票
/
nasdaq-fbrx
/

Forte Biosciences Inc

FBRX

28.685USD

-0.645-2.20%

交易中（美東）報價延遲15分鐘

359.25M總市值

虧損本益比TTM



Forte Biosciences Inc

28.685

-0.645-2.20%

概覽公司財務分析

概覽

公司

財務

分析

關於 Forte Biosciences Inc 公司

Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is an anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. It is advancing clinical development of FB102 into patient-based trials for celiac disease and non-segmental vitiligo. The Company's FB102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D). Its subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Australia Proprietary Limited.

Forte Biosciences Inc簡介



公司代碼FBRX

公司名稱Forte Biosciences Inc

上市日期Apr 13, 2017

CEOWagner (Paul A)

員工數量14

證券類型Ordinary Share

年結日Apr 13

公司地址3060 Pegasus Park Drive

城市DALLAS

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編75247

電話13106186994

網址https://www.fortebiorx.com/home/default.aspx

公司代碼FBRX

上市日期Apr 13, 2017

CEOWagner (Paul A)

Forte Biosciences Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. Paul A. Wagner, Ph.D.

Chairman of the Board, President, Chief Executive Officer

82.09K

+1.42%

Mr. Antony A. Riley

Chief Financial Officer

31.70K

+0.77%

Mr. David W. (Dave) Gryska

Independent Director

5.94K

Mr. Steven Kornfeld

Independent Director

3.96K

Dr. Barbara K. Finck, M.D.

Director, Senior Medical Clinician

Dr. Stephen K. Doberstein, Ph.D.

Independent Director

Mr. Richard G. (Rich) Vincent, CPA

Independent Director

Dr. Scott C. Brun, M.D.

Independent Director

Mr. Shiv Kapoor

Independent Director

名稱

名稱/職務

職務

持股

持股變動

Dr. Paul A. Wagner, Ph.D.

Chairman of the Board, President, Chief Executive Officer

82.09K

+1.42%

Mr. Antony A. Riley

Chief Financial Officer

31.70K

+0.77%

Mr. David W. (Dave) Gryska

Independent Director

5.94K

Mr. Steven Kornfeld

Independent Director

3.96K

Dr. Barbara K. Finck, M.D.

Director, Senior Medical Clinician

Dr. Stephen K. Doberstein, Ph.D.

Independent Director

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 11月17日週一

持股股東

股東類型

持股股東

佔比

Fred Alger Management, LLC

13.06%

Federated Hermes Global Investment Management Corp.

13.05%

Janus Henderson Investors

11.21%

OrbiMed Advisors, LLC

9.56%

Tybourne Capital Management (HK) Limited

6.28%

其他

46.84%

持股股東

佔比

Fred Alger Management, LLC

13.06%

Federated Hermes Global Investment Management Corp.

13.05%

Janus Henderson Investors

11.21%

OrbiMed Advisors, LLC

9.56%

Tybourne Capital Management (HK) Limited

6.28%

其他

46.84%

股東類型

持股股東

佔比

Investment Advisor/Hedge Fund

46.88%

Hedge Fund

20.01%

Private Equity

9.56%

Investment Advisor

7.18%

Corporation

3.92%

Individual Investor

1.02%

Research Firm

0.12%

其他

11.31%

機構持股



更新時間: 12月8日週一

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

10.85M

55.59%

2025Q3

10.85M

55.60%

+222.21K

2025Q2

10.20M

43.87%

+4.95M

2025Q1

5.29M

79.85%

+32.05K

2024Q4

5.16M

31.17%

+3.22M

2024Q3

789.31K

58.51%

-26.11K

2024Q2

815.46K

58.79%

-11.24K

2024Q1

101

826.69K

59.45%

-38.71K

2023Q4

113

819.35K

60.39%

+5.27K

2023Q3

130

814.23K

49.33%

+164.66K

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Fred Alger Management, LLC

1.62M

13.02%

+708.04K

+77.75%

Jun 30, 2025

Federated Hermes Global Investment Management Corp.

1.48M

11.89%

+406.41K

+37.90%

Aug 31, 2025

Janus Henderson Investors

1.39M

11.22%

+474.85K

+51.61%

Jun 30, 2025

OrbiMed Advisors, LLC

1.20M

9.63%

+603.87K

+101.82%

Jun 30, 2025

Tybourne Capital Management (HK) Limited

786.65K

6.33%

+166.67K

+26.88%

Jun 30, 2025

The Vanguard Group, Inc.

486.92K

3.92%

+397.97K

+447.40%

Jun 30, 2025

Cable Car Capital LLC

500.00K

4.02%

+280.40K

+127.68%

Jun 30, 2025

Sphera Funds Management Ltd.

495.11K

3.98%

+495.11K

Jun 30, 2025

Nemean Asset Management, LLC

432.28K

3.48%

+432.28K

Nov 22, 2024

Adage Capital Management, L.P.

333.33K

2.68%

+333.33K

Jun 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

Alger 35 ETF

1.35%

Texas Capital Texas Small Cap Equity Index ETF

0.06%

iShares Micro-Cap ETF

0.01%

Dimensional US Core Equity 1 ETF

iShares Core S&P Total U.S. Stock Market ETF

Fidelity Nasdaq Composite Index ETF

Alger Mid Cap 40 ETF

Avantis US Small Cap Equity ETF

Alger 35 ETF

佔比1.35%

Texas Capital Texas Small Cap Equity Index ETF

佔比0.06%

iShares Micro-Cap ETF

佔比0.01%

Dimensional US Core Equity 1 ETF

佔比0%

iShares Core S&P Total U.S. Stock Market ETF

佔比0%

Fidelity Nasdaq Composite Index ETF

佔比0%

Alger Mid Cap 40 ETF

佔比0%

Avantis US Small Cap Equity ETF

佔比0%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

Aug 22, 2024

Merger

25→1

Aug 22, 2024

Merger

25→1

Aug 22, 2024

Merger

25→1

Aug 22, 2024

Merger

25→1

Jun 15, 2020

Merger

15→1

Jun 15, 2020

Merger

15→1

公告日期

類型

比率

Aug 22, 2024

Merger

25→1

Aug 22, 2024

Merger

25→1

Aug 22, 2024

Merger

25→1

Aug 22, 2024

Merger

25→1

Jun 15, 2020

Merger

15→1

Jun 15, 2020

Merger

15→1

Jun 15, 2020

Merger

15→1

Jun 15, 2020

Merger

15→1

常見問題

Forte Biosciences Inc的前五大股東是誰？



Forte Biosciences Inc的前五大股東如下：
Fred Alger Management, LLC
持有股份：1.62M
佔總股份比例：13.02%。
Federated Hermes Global Investment Management Corp.
持有股份：1.48M
佔總股份比例：11.89%。
Janus Henderson Investors
持有股份：1.39M
佔總股份比例：11.22%。
OrbiMed Advisors, LLC
持有股份：1.20M
佔總股份比例：9.63%。
Tybourne Capital Management (HK) Limited
持有股份：786.65K
佔總股份比例：6.33%。